Voluntary announcement - poster presentation of latest clinical data for senaparib and PARP1-selective inhibitors IMP1734 and IMP1707 at 2026 esmo congress
Filed with HKEX · Stock code 7630 ·
6ix is reading this filing.
View original source (HKEXnews)IMPACT Therapeutics, Inc. on 6ix
Earlier from IMPACT Therapeutics
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - positive CHMP opinion for senaparib, as potential first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer
- 2026 Interim Report
- IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
- Articles of association
Follow IMPACT Therapeutics into a list and get an email when it puts out news.
Follow IMPACT Therapeutics